Exodus Point Capital Management, LP Altimmune, Inc. Transaction History
Exodus Point Capital Management, LP
- $11.4 Billion
- Q2 2025
A detailed history of Exodus Point Capital Management, LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 39,259 shares of ALT stock, worth $154,287. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,259
Previous 40,927
4.08%
Holding current value
$154,287
Previous $205,000
25.85%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ALT
# of Institutions
221Shares Held
36.5MCall Options Held
4.92MPut Options Held
4.18M-
Black Rock Inc. New York, NY5.32MShares$20.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.17MShares$20.3 Million0.0% of portfolio
-
State Street Corp Boston, MA2.75MShares$10.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$10.8 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA1.93MShares$7.6 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $193M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...